Note: This column describes the author’s own experiences with several antidepressants and other mental health medications. Not everyone will have the same response to treatment. Consult your doctor before starting or stopping a therapy. I touched on it in my previous column, but I’d just like to say that…
A recent case report highlights how acute intermittent porphyria (AIP) should be considered early in the process of diagnosis when patients show certain brain symptoms and heart problems. The brain conditions documented are posterior reversible encephalopathy syndrome (PRES), which is marked by swelling in parts of the brain, and…
The case of a 16-year-old girl with recurrent acute intermittent porphyria (AIP) attacks who saw her symptoms ease after she started treatment with Givlaari (givosiran) has been reported in the U.S. The injectable therapy in the U.S. is approved only for adults with acute forms of porphyria, unlike…
“You can go with them,” I told my husband, Daniel, as I lay in the hospital bed. “Go where?” he asked. “Out the window,” I responded. Considering we were on one of the top floors of the hospital, Daniel was very confused. Anyone would’ve struggled to grasp what was going…
The dosing of Givlaari (givosiran) may be personalized for people with acute intermittent porphyria (AIP), who are in stable condition after one year of treatment. That’s according to a recent study that described the cases of three women for whom treatment normalized the levels of delta-aminolevulinic acid (ALA),…
Pain is a complex and deeply personal experience that defies easy descriptions. It binds us all in a shared human condition. For those living with porphyria, pain isn’t just a symptom; it’s an overwhelming and often misunderstood aspect of daily life. I’ve watched my youngest son struggle with…
By combing through a database from the U.S. Food and Drug Administration (FDA), scientists in China have compiled a list of more than 50 medications that can trigger porphyria attacks. Their findings were reported in the study, “Drug-associated porphyria: a pharmacovigilance study,” published in the Orphanet Journal…
This column describes the author’s own experiences with several medicines. Not everyone will have the same response to treatment. Consult your doctor before starting or stopping a therapy. I was 23 and in a relationship with my eventual husband, Daniel. At the time, we weren’t ready to have a baby,…
Givlaari (givosiran) safely led to a complete resolution of annual attacks in people with acute hepatic porphyria (AHP), according to real-world data from a case series study in Italy. Long-term treatment also led to sustained reductions in key markers of AHP, along with gains in physical function. A trend for…
Scenesse (afamelanotide) increases the time people with erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP), two types of porphyria, can spend in the sun without pain, which may help improve their quality of life, a study has found. The study, “Afamelanotide for Treatment of the Protoporphyrias: Impact on…
Get regular updates to your inbox.
